IP Library Granted Patent US 10,899,760
Granted Patent B2
US 10,899,760 · App. 16/745,418 · Granted Jan 26, 2021

Processes for preparing an FGFR inhibitor

Inventors: Jiang Zhu (San Ramon, CA); Mohammad Masjedizadeh (San Jose, CA)
Assignee: PRINCIPIA BIOPHARMA, INC.
C07D471/04A61P35/00C07B35/02C07B35/06C07B39/00C07B43/04C07B43/06C07B45/04C07B2200/13
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,899,760
App. No.
16/745,418
Granted
Jan 26, 2021
Kind
B2
Abstract

Disclosed herein are processes for preparing 8-(3-(4-acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8H)-one and FGFR inhibitor, as well as polymorphs and/or salt forms thereof.

Claims (25)

1. A process of preparing a compound of formula (I):

comprising:

(A) treating compound of formula (a), where X is a leaving group under elimination reaction conditions, with a base

to provide the compound of formula (I); or

(B) reducing the acetylene bond in compound (b)

to provide the compound of formula (I); or

(C) treating a compound of formula (c) with a reducing agent

to provide the compound of formula (I); or

(D) chlorinating a compound of formula (d)

to provide the compound of formula (I).

2. The process of claim 1 wherein the process comprises treating the compound of formula (a) with a base

to provide the compound of formula (I).

3. The process of claim 1 wherein the process comprises reducing the acetylene bond in compound (b)

to provide the compound of formula (I).

4. The process of claim 1 wherein the process comprises treating a compound of formula (c) with a reducing agent

to provide the compound of formula (I).

5. The process of claim 1 wherein the process comprises chlorinating the compound of formula (d)

to provide the compound of formula (I).

6. The process of claim 2 wherein X is halo, phosphate, mesylate, tosylate, or 1,1,1-trifluoro-N-[(trifluoromethyl)sulfonate.

7. The process of claim 2 wherein the reaction is carried out in an aprotic, polar organic solvent.

8. The process of claim 7 wherein the base is either an organic or an inorganic base.

9. The process of claim 3 wherein the reducing agent is Lindlar catalyst.

10. The process of claim 4 where the reducing agent is sodium borohydride or i-PrMgCl/THF and an organic or inorganic acid.

11. The process of claim 5 wherein the process comprises chlorinating with a chlorinating agent that is N-chlorosuccinimide (NCS), sulfonyl chloride, or sulfuryl chloride.

12. The process of claim 11 wherein the chlorinating agent is NCS, the reaction is carried out in a halogenated hydrocarbon, and in the presence of an organic acid or an organic base.

Assignments (2)
ASSIGNEE CHANGE OF ADDRESS Recorded Sep 16, 2025
From: PRINCIPIA BIOPHARMA INC.
To: PRINCIPIA BIOPHARMA INC.
Reel/Frame 072881/0270 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 18, 2020
From: ZHU, JIANG; MASJEDIZADEH, MOHAMMAD
To: PRINCIPIA BIOPHARMA, INC.
Reel/Frame 052685/0343 →
Continuity (3)
Continuation 15748212
Provisional Application 62203498 · Aug 11, 2015
Related Publication 20200148680A1 · May 14, 2020
Cited By (1)
US 12,281,110